Communiqués IP Group Plc

Actions

IPO

GB00B128J450

Gestion des placements et exploitants de fonds

Marché Fermé - London S.E. Autres places de cotation 17:35:27 08/07/2026			Varia. 5j.	Varia. 1 janv.
63,50 ^GBX	-1,70%		-6,75%	+8,36%

23/06	IP Group rejette la proposition finale de rachat de Railpen	MT
23/06	IP Group rejette une proposition d'OPA « finale » de Railpen	AN

Communiqués

15:18	Form 8.3 - The Vanguard Group, Inc.: IP Group plc	EQ
03/07	The Vanguard Group, Inc.: IP Group plc	EQ
01/07	Form 8.3 - The Vanguard Group, Inc.: IP Group plc	EQ
26/06	Form 8.3 - The Vanguard Group, Inc.: IP Group plc	EQ
25/06	Form 8.3 - The Vanguard Group, Inc.: IP Group plc	EQ
24/06	Form 8.3 - The Vanguard Group, Inc.: IP Group plc	EQ
24/06	Dimensional Fund Advisors Ltd. : Form 8.3 - IP GROUP PLC - Ordinary Shares	AQ
09/06	IP : France doubles down on natural hydrogen as Mantle8 secures exclusive Pyrenees permit	PU
03/06	IP : OQC raises £260m in Europe’s largest ever private quantum computing funding round	PU
02/06	IP : Genomics launches the Mystra AI platform, adopted by industry giants and up-and-coming biotechs	PU
01/06	IP : Audioscenic™ to showcase next-generation spatial audio platform at COMPUTEX Taipei 2026	PU
27/05	IP : Slamcore secures $14m, backed by investors including Rockwell Automation , to scale visual AI across intralogistics	PU
21/05	IP : Oxford Nanopore - London Calling Technology Update	PU
21/05	IP : Oxford Nanopore strengthens executive leadership team	PU
18/05	IP : Microbiotica announces positive Results from its Phase 1b Trial (MELODY-1) of MB097, a precision microbiome co-therapy in advanced melanoma	PU
14/05	IP : Proposed New Articles of Association	PU
13/05	IP : Artios announces clinical trial collaboration with GSK to evaluate Alnodesertib in combination with Risvutatug Rezetecan, a B7-H3-targeted ADC in gastrointestinal tumors	PU
13/05	IP : Mantle8 raises €31m in Series A funding to prove commercial viability of natural hydrogen production	PU
12/05	IP : Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001	PU
08/05	IP : Quantum Motion Raises $160m Series C to Deliver Quantum Computing’s “Transistor Moment”	PU
01/05	IP : First Light Fusion announces sale of VIPER III velocity amplifiers to Texas A&M Engineering Experiment Station	PU
29/04	IP : Hypervision Surgical Raises £17 Million Series A to Power Surgical Intelligence Through Hyperspectral Vision	PU
29/04	IP : Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases	PU
23/04	IP : Locai Labs signs contract with First Light Fusion for the supply of a domain-specific LLM for fusion energy research	PU
22/04	IP : Impact Report 2025 report (ip group impact report 2025)	PU